Cem Zorlular, CEO of Er-Kim Pharmaceuticals, shares his insights on how pharma manufacturers can better navigate the global commercialisation of treatments in an ever-changing landscape.
Key insights:
- Understanding updates pertaining to revised legislation and pharma manufacturing guidelines globally can assist manufacturers in meeting requirements for commercialising therapies.
- Close collaboration with well-established distribution partners on a launch strategy that includes managing early access, pharmacovigilance, and security solutions can minimise the risk to the supply chain and patients.
- Operating in international markets can be risky when it comes to healthcare and anti-bribery compliance, and finding a local partner with a top-down management commitment to compliance is critical.
While there is regulation and governance in place in most countries to protect companies and patients in the marketing and consumption of drugs, manufacturers need to keep their finger on the pulse for updates, and local partners can help. Understanding updates pertaining to revised legislation and pharmaceutical manufacturing guidelines globally can assist manufacturers in meeting requirements for commercialising therapies. How can companies mitigate the risk of unlawful promotion and distribution of treatments – among other things – to ensure the delivery of vital treatments to patients?